APA (7th ed.) Citation

NP, S., S, J., B, R., SR, P., JK, G., VS, C., . . . VGM, N. (2023). AKR1B1 inhibition using NARI-29-an Epalrestat analogue-alleviates Doxorubicin-induced cardiotoxicity via modulating Calcium/CaMKII/MuRF-1 axis. Chemico-biological interactions, 381, 110566. https://doi.org/10.1016/j.cbi.2023.110566

Chicago Style (17th ed.) Citation

NP, Syamprasad, Jain S, Rajdev B, Panda SR, Gangasani JK, Challa VS, Vaidya JR, Kundu GC, and Naidu VGM. "AKR1B1 Inhibition Using NARI-29-an Epalrestat Analogue-alleviates Doxorubicin-induced Cardiotoxicity via Modulating Calcium/CaMKII/MuRF-1 Axis." Chemico-biological Interactions 381 (2023): 110566. https://doi.org/10.1016/j.cbi.2023.110566.

MLA (9th ed.) Citation

NP, Syamprasad, et al. "AKR1B1 Inhibition Using NARI-29-an Epalrestat Analogue-alleviates Doxorubicin-induced Cardiotoxicity via Modulating Calcium/CaMKII/MuRF-1 Axis." Chemico-biological Interactions, vol. 381, 2023, p. 110566, https://doi.org/10.1016/j.cbi.2023.110566.